The effects of bupropion on negative symptoms in schizophrenia
Not Applicable
- Conditions
- egative symptoms in schizophrenia.
- Registration Number
- IRCT2013100114850N1
- Lead Sponsor
- Yazd medical science university of shahid sadughi
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Inclusion:age of 15 to 60 years old, presence of negative symptoms
Exclusion:presence of depression,substance abuse,suicidal ideation,sever psychosis,sever medical illness,pregnancy and lactation
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method egative symptoms. Timepoint: Onset and end of trial. Method of measurement: Scale for the assessment of negative symptoms inquirement.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bupropion's effect on negative symptoms in schizophrenia?
How does bupropion compare to standard dopamine agonists in treating negative symptoms of schizophrenia?
Are there specific biomarkers that predict response to bupropion in schizophrenia patients with negative symptoms?
What are the potential adverse events associated with bupropion use in schizophrenia and how can they be managed?
What combination therapies involving bupropion show promise for addressing negative symptoms in schizophrenia?